The Imperial College London Diabetes Centre (ICLDC), part of the M42 group, will open a dedicated one-stop facility in Madinat Zayed to provide comprehensive care for diabetes and endocrine patients. With a proven track-record of nearly two decades, ICLDC’s model for diabetes prevention and management has significantly reduced HbA1c values in patients across the UAE. The new tech-enabled, world-class centre in Al Dhafra will serve a critical part of Abu Dhabi’s population, providing targeted prevention and intervention for more than 6,000 diabetes sufferers in the region.
Set to open in the second half of 2024, the state-of-the-art facility will bring comprehensive care closer to those in need and cut travel time by more than 75 per cent. Currently, the flagship ICLDC in Abu Dhabi city serves around 9 per cent of the Al Dhafra population with diabetes. The new facility in Madinat Zayed will provide greater access across Al Dhafra including residents in Liwa, Mirfa, Gayathi, Ruwais and Tarif. In addition to providing clinical care, ICLDC will continue to promote preventive solutions for Type 2 diabetes, with an extensive community outreach programme including workshops, health screenings, and educational programmes for schools and organisations, as well as promoting an active lifestyle and healthy eating.
Hasan Jasem Al Nowais, Managing Director and Group Chief Executive Officer at M42, said: “M42 is committed to providing world-class preventive and personalised health solutions that enable individuals to put their health back in their own hands. As a leader in diabetes and endocrine management and prevention, the Imperial College London Diabetes Centre is positively impacting lives across the UAE. Expanding our one-stop services to Al Dhafra presents an opportunity to serve a much greater number of UAE residents with an innovative model that provides premium, tech-enabled health solutions that result in tangible positive clinical outcomes.”
ICLDC has played a key role in revolutionising population health in the UAE over the past twenty years. ICLDC’s efforts have led to a notable decrease in HbA1c levels, dropping from an average of 9.5 per cent to 7.2 per cent among its patients. 57 per cent of ICLDC’s patients now have HbA1c results below 7 per cent, surpassing the international benchmark of 38 per cent. These outcomes demonstrate the expertise and commitment of the team of over 65 consultants in diabetes and endocrine care across ICLDC’s facilities.
The Al Dhafra ICLDC centre will be equipped with the latest diagnostic and management facilities supported by a world-class multi-specialty team. The centre will operate state-of-the-art outpatient services, providing specialised care for diabetes and endocrine related complications.
Dr Mai Al Jaber, Chief Executive Officer of ICLDC, said: "Today, the need for accessible and comprehensive care has never been more apparent. Serving more of the Al Dhafra population is an honour and a duty we are fully committed to. Our aim is to provide patients with the best patient-centric and comprehensive diabetes and endocrinology solutions, under one roof and closer to home."
ICLDC's Madinat Zayed facility will be the fourth dedicated centre in the UAE, in addition to a satellite clinic based in Mubadala Health Dubai, offering integrated diabetes and endocrine treatment services.
The new clinic’s patient journey will provide comprehensive services from registration to consultations and pharmacy support.
